Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...

Learn more about whether Option Care Health, Inc. or Surgery Partners, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Do we have enough trained oncologists and medical professionals in India to man these over 4,500 beds in the public sector?

In Part 7 – the final instalment of our inaugural Life Sciences Industry Report – we look more closely at reporting from 2024 ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

These are known as disease-modifying treatments and have been licensed for private use. Other medications are under review to see if they could be prescribed to people in the very early stages of ...